StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Gyre Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 93.4%. For fiscal 2025 it was 95.4%, against 96.3% the year before. The highest annual figure on record is 97.2% in fiscal 2009.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202595.4%−1.0
FY2024Dec 31, 202496.3%+0.4
FY2023Dec 31, 202395.9%+0.6
FY2022Dec 31, 202295.3%−1.9
FY2009Dec 31, 200997.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202694.1%+5.6
Q2 FY2026Jun 30, 202692.4%+6.2
Q1 FY2026Mar 31, 202694.6%−1.4
Q4 FY2025Dec 31, 202592.6%−3.2
Q3 FY2025Sep 30, 202588.5%−7.7
Q2 FY2025Jun 30, 202586.2%−10.8
Q1 FY2025Mar 31, 202595.9%−0.4
Q4 FY2024Dec 31, 202495.8%+0.4
Q3 FY2024Sep 30, 202496.2%−0.1
Q2 FY2024Jun 30, 202496.9%+0.6
Q1 FY2024Mar 31, 202496.4%+0.9
Q4 FY2023Dec 31, 202395.4%–
Q3 FY2023Sep 30, 202396.3%–
Q2 FY2023Jun 30, 202396.3%–
Q1 FY2023Mar 31, 202395.5%–

More Gyre Therapeutics figures

See a number that looks wrong?